BridgeBio's stock rockets 66% on news of positive results from late-stage trial of ATTR-CM treatmentMarket Watch • 07/17/23
BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)GlobeNewsWire • 07/17/23
BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023GlobeNewsWire • 07/14/23
Burjeel Holdings to Launch Rare Disease Research & Development Project ‘NADER' in Partnership with US-based BridgeBio PharmaGlobeNewsWire • 07/12/23
BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual ConferenceGlobeNewsWire • 06/20/23
BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual ConferenceGlobeNewsWire • 06/08/23
BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual MeetingGlobeNewsWire • 05/22/23
BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual MeetingGlobeNewsWire • 05/15/23
BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business UpdateGlobeNewsWire • 05/04/23
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare ConferenceGlobeNewsWire • 04/27/23
BridgeBio Pharma (BBIO) Moves 9.7% Higher: Will This Strength Last?Zacks Investment Research • 03/27/23
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb's OPDIVO® (nivolumab)GlobeNewsWire • 03/23/23
BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)GlobeNewsWire • 03/21/23
BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)GlobeNewsWire • 03/17/23